Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AHCT intensification + teclistamab + daratumumab
- Development stage
- Phase 2
- Lead developer
- Johnson & Johnson
- Modality
- Cell Therapies, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
AHCT intensification + teclistamab + daratumumab is a multi-phase combination treatment regimen evaluated in the MASTER-2 phase 2 clinical trial (NCT05231629) for patients with newly diagnosed multiple myeloma (NDMM). The regimen is specifically utilized for patients who remain minimal residual disease (MRD) positive after induction therapy with daratumumab, bortezomib, lenalidomide, and dexamethasone (Dara-VRd). It consists of autologous hematopoietic cell transplantation (AHCT) using melphalan conditioning as an intensification step, followed by consolidation and maintenance phases using a combination of teclistamab (a BCMA x CD3 bispecific T-cell engager) and daratumumab (a CD38-targeting monoclonal antibody). This MRD-guided approach aims to achieve deep, sustained responses by intensifying therapy in patients with persistent disease after initial induction.
- Other names
- AHCT intensification + Tec-Dara consolidation + Tec-Dara maintenanceDara-TecDara-Tec consolidationDara-Tec maintenanceAHCT + teclistamab + daratumumab
02
Targets
BCMA (B-cell maturation antigen)CD3 (T-cell surface glycoprotein CD3)CD38 (Cluster of Differentiation 38)
Beyond the preview
Go deeper on AHCT intensification + teclistamab + daratumumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AHCT intensification + teclistamab + daratumumab.